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FUNCTIONS OF THE HOMEOBOX GENE DLX4 IN CONTROLLING
INFLAMMATORY SIGNALING AND METASTASIS OF EPITHELIAL OVARIAN
CANCER

Dhwani Haria, B.S.

Advisory Professor: Honami Naora, Ph.D.

Epithelial ovarian cancer (EOC) accounts for the most number of deaths among women
with gynecological malignancies in the United States. Approximately 80% of EOC patients
are diagnosed with disease that has disseminated beyond the confines of the ovaries. The five
year survival rate for patients with advanced stage EOC is less than 30% and the recurrence
of chemoresistant disease is high. Identifying the mechanisms that control peritoneal
metastasis of EOC is therefore critical for improving treatment of advanced stage disease.
The homeobox gene DLX4 encodes a transcription factor that is absent from most normal
adult tissues. Previous studies from our laboratory have identified that DLX4 is highly
expressed in advanced stage EOC and is strongly associated with reduced survival. The
underlying hypothesis of my study is that DLX4 promotes peritoneal dissemination of EOC.
The overall goal of my study is to determine the role and mechanisms of DLX4 in controlling
peritoneal metastasis of EOC. My specific aims are: 1) to determine whether DLX4 promotes
peritoneal dissemination of EOC, and 2) to identify the mechanisms by which DLX4 controls
tumor–peritoneum interactions. Firstly, my studies have identified that DLX4 promotes EOC
dissemination by inducing expression of the cell adhesion molecule CD44 which is a major

v

receptor for hyaluronan, a glycosaminoglycan that is expressed on mesothelial cells lining
the peritoneal cavity and abdominal organs. Secondly, my studies have identified that DLX4
induces CD44 expression by activating the pro-inflammatory cytokine interleukin 1-beta (IL1β) which in turn stimulates the nuclear factor kappa B (NF-κB) signaling pathway. This
study provides insights into the mechanisms of peritoneal metastasis of EOC and raises the
possibility that targeting inflammatory signaling could be a strategy for treatment of
advanced stage EOC.
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CHAPTER 1: INTRODUCTION
A. BIOLOGY OF OVARIAN CANCER
1. Classification and Clinical Staging of Ovarian Cancer
Ovarian cancer accounts for the highest lethality among women with gynecologic
malignancies in the United States 1. Ovarian cancers are classified as 1) epithelial tumors, 2)
sex cord stromal tumors and 3) germ cell tumors. Epithelial ovarian cancers (EOC) constitute
about 60% of all ovarian tumors and 90% of malignant tumors 2. It has been traditionally
thought that EOC originates from the ovarian surface epithelium. However, recently, the
fallopian tube and some other epithelial tissues have been reported as origins for EOC

3, 4

.

EOC is a heterogeneous disease and is categorized into different subtypes based on their
histologic features 2. These histologic subtypes exhibit different types of mutations (Table 1).
The serous subtype is the most common form of EOC (Figure1) 5, 6. The stage of the disease,
i.e. its spread within the ovaries or to other parts of the body is evaluated during surgery
(Table 2) 7. Due to a lack of distinctive symptoms and specific diagnostic biomarkers, more
than 60% of EOC patients are diagnosed with disease that has already spread throughout the
peritoneal cavity (Figure 2) 8. In contrast, only 15% of EOC patients present with ovarianconfined disease at the time of initial diagnosis (Figure 2) 8. The five-year survival rate for
women with advanced-stage EOC is less than 30% as compared to over 90% for women
with localized disease (Figure 2) 8. The majority of patients with advanced-stage EOC who
undergo tumor-debulking surgery and conventional platinum-taxane chemotherapy relapse
within 18 months 9.

1

Table 1: Common mutations identified in the histologic subtypes of EOC

Histologic subtype

Mutations

Serous

High grade serous:
TP53
CDKN2A
BRCA1/2
Low grade serous:
BRAF
KRAS
ERBB2

Endometrioid

CTNNB1
PIK3CA
PTEN
ARID1A

Mucinous

KRAS

Clear cell

HNF1B
PTEN
ARID1A
PIK3CA

2

References

10-12

5, 13

5, 14

5, 15-17

Frequencies of subtypes of EOCs
80
70

68%

60
50
40
30
20

10%

7%

10

3%

0

Serous

Endometrioid

Mucinous

Clear cell

Figure 1. Relative frequencies of subtypes of EOC
Relative frequencies of subtypes of EOCs as reported by two independent studies 5, 6.
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Table 2: International Federation of Gynecology and Obstetrics (FIGO) staging of
EOC7

FIGO Stage

Characteristics of the tumor

I

Tumor is confined to the ovaries

II

Tumor involves one of both ovaries with extension and/or
implantation on pelvic organs e.g. uterus and/or fallopian tubes

III

Tumor involves one or both ovaries with disease that has spread to
the peritoneum outside the pelvis and/or to retroperitoneal lymph
nodes

IV

Distant metastases to liver, spleen and extra-abdominal organs
with development of pleural effusions

4

Percent of EOC cases by tumor stage
70

61%

60
50
40
30
20

15%

18%
6%

10
0

Localized

Regional

Distant

Unknown

Five-year survival rate
100

92.3%
71.7%

80
60
40

27.4%

21.8%

20
0

Localized

Regional

Distant

Unknown

Figure 2. Stage distribution of EOC and five-year survival rate by stage 8.
(A) Percentage of EOC cases by tumor stage as reported by SEER, where localized disease
corresponds to FIGO Stage I, regional disease corresponds to FIGO stage II and distant
disease corresponds to FIGO Stages III and IV. (B) Five-year survival rate by tumor stage.

5

Currently, the most commonly used biomarker for EOC is the glycoprotein cancer
antigen-125 (CA-125) 18. Serum levels of CA-125 are found to be elevated in approximately
80% of advanced-stage EOC cases and is used for post-operative monitoring 18, 19. However,
measurement of CA-125 is not highly sensitive for detection of early stage EOC. CA-125
levels are also elevated in other conditions such as pregnancy, endometriosis, menstruation
and other malignancies like pancreatic, breast, lung, and gastric cancers

20

. There is,

therefore, a critical need for the identification of novel diagnostic biomarkers for early
detection of EOC and new molecular targets for effective treatment against highly metastatic
and chemoresistant EOC.
2. Biology of dissemination of EOC
Unlike most other types of solid tumors, EOC does not typically metastasize via
lymphatic or hematogenous routes 21. In the initial stage, the tumor is confined to one or both
the ovaries. As the disease progresses, the ovarian capsule is disrupted and the tumor first
spreads by directly extending to adjacent organs, for example, uterus and fallopian tubes
(Figure 3)

22

. Distal dissemination of EOC occurs primarily via intraperitoneal seeding

(Figure 4). Exfoliated tumor cells are transported by the circulating peritoneal fluid and
undergo implantation on the mesothelial linings of the peritoneal cavity wall and abdominal
organs (Figures 3,4)

22

. This peritoneal carcinomatosis is commonly associated with

formation of ascites 22.

6

Figure 3. Pattern of spread of EOC
In the early stage, the tumor (shown as red masses) is confined to one or both the ovaries.
Once the ovarian capsule is disrupted, the tumor spreads by direct extension to adjacent
organs. Exfoliated tumor cells are then transported by the circulating peritoneal fluid and
implant on the mesothelial linings of the pelvic cavity wall and abdominal organs. The
omentum is the most common implantation site 22.

7

Figure 4. Model of peritoneal seeding of EOC
Distal spread of EOC cells (shown in red) occurs via ‘seeding’ of the peritoneal cavity. EOC
cells are exfoliated into the peritoneal fluid and form multicellular aggregates to escape
anoikis. Surviving EOC cells are transported by the circulating peritoneal fluid and then
implant on the mesothelial linings of the peritoneal cavity 22.

8

2.1. Implantation of EOC cells on to the peritoneum
The ability of EOC cells to ‘seed’ the peritoneal cavity is a hallmark of this disease. The
attachment of EOC cells to the peritoneal surfaces is a key rate-limiting step. It is thought
that attachment of EOC cells to the peritoneum is mediated via two primary mechanisms: 1)
attachment to the mesothelial cells lining the peritoneal cavity and 2) attachment to the sub23-26

mesothelial extracellular matrix (ECM)

. Mesothelial cells, that are derived from the

mesoderm, form a monolayer that lines the surface of body’s three serosal cavities: pleural,
pericardial and peritoneal 27. The mesothelial cell lining functions as a protective layer and a
non-adhesive surface that facilitates movement of other tissues and plays an essential role in
immune and inflammatory responses

27

. Attachment of EOC cells to mesothelial cells is

mediated by a repertoire of ligands and receptors. The EOC biomarker CA-125 can mediate
tumor cell implantation by binding the glycosylphosphatidyl inositol (GPI)-linked protein
mesothelin that is expressed on mesothelial cells

28, 29

. Integrins are cell surface protein

complexes composed of α and β subunits that have been reported to facilitate attachment of
EOC cells to mesothelial cells and also to the sub-mesothelial ECM 30. Several groups have
demonstrated that β1 integrin mediates binding of EOC cells to peritoneal mesothelial cells
31-33

. On the other hand, several studies have reported that integrins such as β1 and αvβ3

promote EOC metastasis by binding to components of the ECM such as collagen type,
fibronectin, laminin and vitronectin

34-37

. A study by Iwanicki and colleagues demonstrated

that spheroids of EOC cells can gain access to the sub-mesothelial ECM by displacing
mesothelial cells that line the peritoneal organs by utilizing myosin-generated traction force
that is dependent on activation of α5β1 integrin and talin I 38.

9

Cadherins constitute a gene super-family of membrane glycoproteins that facilitate cellcell adhesion via homophilic interactions. Substantial evidence indicates that alteration in
cadherin expression, often termed ‘cadherin switching’ drives tumor progression

39, 40

. The

most well-characterized form of cadherin-switching involves upregulation of N-cadherin and
P-cadherin and downregulation of E-cadherin

39, 40

. Loss of E-cadherin expression and

increase in expression of N-cadherin in advanced stage EOC correlates with poor prognosis
in patients

41

. High expression of P-cadherin has also been found to correlate with reduced

overall survival of EOC patients

41

. P-cadherin facilitates formation of multi-cellular

aggregates of EOC cells, inhibits anoikis and also promotes attachment of EOC cells to
peritoneal mesothelial cells 42.
The most-studied cell adhesion molecule that promotes attachment of EOC cells to the
mesothelial lining is the cell-surface glycoprotein CD44. CD44 proteins are encoded by a
highly conserved gene and are present in different isoforms 43. This heterogeneity among the
different isoforms is due to differential glycosylation and alternative splicing of exons 43. The
smallest isoform CD44s is the most common isoform and is present on the membrane of
most vertebrate cells. However, unlike CD44s, variant isoforms of CD44 are only expressed
on some epithelial cells during embryogenesis, lymphocytes and in certain cancers

44, 45

.

CD44v7 has been reported to promote metastasis of pancreatic adenocarcinomas 46. Another
study reported that CD44v6 interacts with vascular endothelial growth factor-A (VEGF-A)
and hepatocyte growth factor (HGF) to promote tumor angiogenesis 47. Standard and variant
isoforms of CD44 have been detected in EOCs

48

. Expression of CD44s in EOC is an

independent predictor of survival and its expression correlates with poor outcomes and
decreased overall survival

49-51

. CD44 is a major receptor for the glycosaminoglycan,
10

hyaluronic acid (HA) that is synthesized by mesothelial cells lining the peritoneal cavity 52, 53.
CD44 facilitates attachment of EOC cells to peritoneal mesothelial cells by binding to HA 24,
53, 54

. A study by Strobel and colleagues demonstrated that a CD44 neutralizing antibody (Ab)

significantly inhibited EOC cell implantation on peritoneal mesothelial linings in
intraperitoneal (i.p.) xenograft models

55

. However, the mechanisms that induce expression

of CD44 in EOC cells are poorly understood and require further investigation.
2.2. Inflammatory signaling in EOC
A second hallmark of EOC is the formation of ascites

56

. Accumulation of fluid in the

peritoneal cavity stems from increased vessel permeability

57, 58

. VEGF-A is widely

recognized as the causative factor of ascites formation. High levels of VEGF-A have been
demonstrated to induce vascular permeability and stimulate formation of ascites in EOC 59-62.
Ascitic fluid contains a wide range of growth factors, inflammatory cytokines and
chemokines that function via autocrine and paracrine mechanisms and promote tumor
progression 63. Pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8),
interleukin-10 (IL-10) and interleukin-1β (IL-1β) are present in ascites of EOC patients and
are associated with poor outcomes in patients

64

. IL-6 promotes EOC cell growth and also

stimulates chemoresistance and tumor angiogenesis
promote angiogenesis in EOC

69

65-68

. Elevated levels of IL-8 also

. Elevated levels of IL-1β in ascites of EOC patients

significantly correlate with poor histopathological grade and reduced progression-free
survival

70

. Normal and malignant EOC cells as well as activated stromal immune cells are

the major sources of IL-1β 71. Constitutive secretion of IL-1β by EOC cells promotes tumor
invasion by inducing expression of matrix metalloproteinase-1 (MMP-1) and tumor
angiogenesis by stimulating production of VEGF
11

72, 73

. IL-1β promotes inflammatory

signaling in tumors via activation of nuclear factor kappa B (NF-κB) signaling pathway

74

.

Secretion of IL-1β by EOC cells downregulates expression of p53 in stromal fibroblasts and
stimulates NF-κB signaling which in turn leads to an increase in the expression of other
molecules such as IL-8, IL-6 and VEGF

75

. However, the mechanisms by which IL-1β

promotes peritoneal metastasis of EOC are not clear.
2.3. NF-κB signaling in EOC
The NF-κB signaling pathway is activated in many types of tumors. A central
component of the pathway comprises a family of five transcription factors: p50, p52, p65
(RelA), c-Rel and RelB

76

. There are two different pathways for activation of NF-κB

signaling: canonical and non-canonical. The canonical signaling pathway is triggered by
microbial products and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α)
and IL-1 leading to activation of RelA or c-Rel, which form dimers with p50 77. The dimers
interact with inhibitors of NF-κB family of proteins (IκBα, IκBβ, and IκBε) in the cytoplasm
and are in an inactive state. When the canonical pathway is triggered, the IκB proteins get
phosphorylated by the IκB kinases (IKKs) on conserved serine residues and in turn IκB
proteins undergo degradation by the ubiquitin-proteasome pathway and release the NF-κB
dimers. The dimers then translocate to the nucleus and function as transcription factors to
activate target genes (Figure 5) 77. The non-canonical signaling pathway is activated by TNFfamily cytokines like B-cell activating factor (BAFF), lymphotoxin B, CD40 ligand (CD40L)
and receptor activator of NF-κB ligand (RANKL), which results in the activation of
RelB/p52 complexes. Whereas the canonical pathway is typically regulated by the IKKβ and
IKKγ subunits, the non-canonical pathway is regulated by IKKα which phosphorylates and
processes p100, the precursor form of p52 (Figure 5)
12

77, 78

. Although NF-κB signaling is

widely activated in solid tumors, there are no known oncogenic mutations in members of the
NF-κB family. The activation of this pathway, therefore, has largely been attributed to
inflammatory signals in the tumor microenvironment 79.
The ovarian tumor microenvironment contains a wide variety of pro-inflammatory
cytokines that are secreted by tumor cells and stromal cells. High levels of TNF-α, IL-1α, IL1β and IL-6 have been detected in EOC tissues as compared to levels in normal ovarian
tissues

80-82

. Several studies have demonstrated that high levels of cytokines such as TNF-α

and IL-1β in EOC promote tumor progression by activation of NF-κB signaling

75, 83

. For

example, a study by Kulbe and colleagues identified that TNF-α, through its activation of
NF-κB, upregulates expression of the chemokine receptor CXCR4 which in turn interacts
with its ligand CXCL12, and promotes increased tumor growth and migration

83

. Activation

of the NF-κB pathway in turn induces downstream target genes that encode ligands that
activate the pathway such as TNF-α and IL-1β, and also other target genes encoding IL-6, IL8, VEGF and MMPs 74. This NF-κB signaling loop leads to activation of chronic signaling in
tumors. A number of independent studies have demonstrated a strong association between
activation of NF-κB transcription factors in EOC and poor outcomes in patients

84, 85

. Higher

expression of NF-κB transcription factors such as p50 and p65 has been detected in
advanced-stage EOCs as compared to borderline and benign tumors or normal ovaries

85

.

Levels of phosphorylated p65 in EOC strongly correlate with advanced disease stage and
high tumor grade

86, 87

. However, the mechanisms by which chronic NF-κB signaling

promotes peritoneal dissemination of EOC are poorly understood.
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Figure 5: NF-κB signaling pathway
The canonical NF-κB signaling pathway is triggered by proinflammatory cytokines such as
TNF-α and IL-1β whereas the non-canonical NF-κB signaling pathway is triggered by
cytokines such as lymphotoxin B, CD40L, BAFF and RANKL. These signals lead to
activation of the IKK complex (shown in blue). In the canonical pathway, the IKK complex
phosphorylates IκB (shown in green) at two serine residues, which signals it for degradation
and release of the phosphorylated NF-κB dimers (shown in orange). The NF-κB dimers then
translocate to the nucleus and induce transcription of target genes

88

. Activation of the IKK

complex in the non-canonical pathway leads to phosphorylation and degradation of p100,
releasing p52-RelB heterodimers (shown in yellow). The heterodimers then translocate to the
nucleus and activate transcription of target genes 89.
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B. HOMEOBOX GENES
1. General overview of homeobox genes
Homeobox genes consist of a large super-family of approximately 200 vertebrate genes
that play essential roles in body plan specification and development of virtually all organ
systems during embryogenesis

90, 91

. In adults, homeobox genes regulate tissue homeostasis

and regeneration, differentiation of hematopoietic progenitors and vascular remodeling

92, 93

.

Homeobox genes were first identified due to their mutations in Drosophila that caused
formation of body segments in the wrong context. For example, loss-of-function mutations in
the Antennapedia gene in Drosophila results in development of ectopic antennae instead of
legs

94

. Similarly, in humans, aberrant expression of homeobox genes can cause

developmental defects like malformation of limbs or other sensory defects

95, 96

. Homeobox

genes encode proteins termed ‘homeoproteins’ that primarily function as transcription factors
97, 98

. Homeoproteins consist of a highly conserved DNA binding domain that is known as the

‘homeodomain’. This homeodomain forms three alpha-helices which binds DNA elements
having TAAT core motifs (Figure 6) 99.
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Figure 6. Structure of the homeodomain
Transcription factors encoded by homeobox genes consist of a highly conserved 61 amino
acid DNA binding domain termed the ‘homeodomain’. The homeodomain forms three αhelices (colored boxes) that bind DNA elements containing TAAT core motifs 99.
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2. Genomic organization of homeobox genes
In mammals, homeobox genes are classified into different families based on the
similarities in their homeodomains and functional motifs

100

. Mammalian homeobox gene

families are named after their homologs in Drosophila. For example, members of the
mammalian gene families DLX, CDX, and OTX are named after homologous Drosophila
gene families distal-less, caudal, and orthodenticle respectively

101

. Eventhough many

homeobox genes in mammals are dispersed throughout the genome, members of HOX and
DLX gene families are arranged in clusters

102, 103

. The 39 members of the mammalian HOX

gene family are grouped in clusters on four different chromosomes (Figure 7)

104, 105

.

Likewise, the six members of the mammalian DLX gene family are arranged in bigene
clusters and are located upstream of the HOX gene clusters (Figure 7)

105, 106

. It has been

postulated that clusters of HOX and DLX gene families derived from gene duplication during
evolution 103, 107.
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Figure 7. Clusters of HOX and DLX gene families
The 39 members of the mammalian HOX gene family are organized in clusters on 4 different
chromosomes. The 6 members of the DLX gene family are arranged in bigene clusters,
located upstream of the HOX loci

105, 106

.
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3. Deregulation of homeobox genes in tumors
Substantial evidence indicates that expression of several homeobox genes is deregulated
in a wide variety of tumors 97. Deregulation of homeobox genes in cancer falls into two broad
categories. The first category of homeobox genes are those that are usually expressed only in
normal, differentiated adult tissues but are often downregulated in tumors and have tumor
suppressive functions (Figure 8)

97, 99, 101

. Loss of expression of these homeobox genes has

been attributed to epigenetic mechanisms, long non-coding RNAs and chromosomal
101

aberrations like loss of heterozygosity

. For example, loss of HOXA5 in breast cancers

occurs due to promoter hypermethylation 108. Loss of HOXA5 results in a down-regulation of
p53 expression and tumor progression in breast cancers

108

. The long non-coding RNA

HOTAIR which is located in the HOXC locus binds to and re-targets Polycomb Repressive
Complex 2 (PRC2), a large multi-protein complex that mediates transcriptional silencing 109,
110

. HOTAIR re-targets the PRC2 complex to the HOXD locus

109

. In breast cancers,

increased expression of HOTAIR in primary tumors is considered to be highly predictive of
metastatic disease and poor outcomes

109

. The homeobox gene NKX3.1, which maps to

chromosomal region 8p21, is expressed in fetal and adult prostate tissues and controls normal
differentiation of prostatic epithelium

111, 112

. Loss of heterozygosity of NKX3.1 occurs in

approximately 60%-80% of prostate cancers

113

. Loss of NKX3.1 induces development of

prostatic intraepithelial neoplasia (PIN) 114. Furthermore, loss of NKX3.1 coupled with loss of
the tumor suppressor gene PTEN and overexpression of oncogene c-myc promotes prostate
cancer progression 115-118.
The second category of homeobox genes are those that are usually expressed in
embryonic tissues but not in adult tissues. These homeobox genes are often upregulated in
19

tumors and have tumor promoting functions (Figure 8)

97, 99, 101

. Gain of function of

homeobox genes in tumors can be caused by chromosomal aberrations like gene
amplification 101. For example, the HOXB gene cluster and the homeobox gene DLX4 map to
the 17q21.3-q22 region, a chromosomal hotspot amplified in about 10% of breast cancers
and EOC

119-121

. HOXB7 is also overexpressed in various other types of tumors such as

pancreatic cancer, colorectal cancer and melanomas

122-124

. High expression of HOXB7 in

breast cancers, EOC and melanomas drives tumor progression in part by activating
transcription of the gene that encodes basic fibroblast growth factor (bFGF)

122, 125-127

.

HOXB7 also promotes resistance to tamoxifen in breast cancers by inducing expression of
epidermal growth factor receptor (EGFR) and its ligands, thereby activating EGFR signaling
128

. HOXB7 and DLX4 are over-expressed in more than 50% of breast cancers and EOC

though only 10% of cases exhibit a loss of the chromosomal region containing the gene
cluster

129, 130

. This highlights the need to identify more mechanisms of homeobox gene

deregulation as well as downstream transcriptional targets that will aid in developing better
targeted therapies.
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Figure 8. Trends in the aberrant expression of homeobox genes in tumors
Homeobox genes that are normally expressed only in embryonic tissues are often activated in
tumors and generally have tumor-promoting functions (shown in orange). Homeobox genes
that are normally expressed in normal differentiated adult tissues are down-regulated in
tumors and generally have tumor-suppressive functions (shown in yellow) 101.
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Table 3: Examples of significance of aberrant homeobox gene expression in tumors

Homeobox
gene

Type of cancer

Expression
pattern
in tumors

Functional significance of
deregulation in tumors


HOXB7

melanoma, breast,
pancreatic,
colorectal, ovarian





HSIX1

breast,
pancreatic,
rhabdomyosarcomas




HOXA9

ovarian,
glioblastomas



NKX3.1



prostate



HOXA5

breast




CDX2

colorectal


22

Induces expression of EGFR
and FGF2
Promotes tumor growth and
angiogenesis
Promotes EMT and
chemoresistance
Promotes tumor growth by
inducing cyclin A1
Promotes lymphangiogenesis
and metastasis by inducing
VEGF-C and ezrin expression
Promotes EOC growth by
stimulating cancer-associated
fibroblasts and macrophages
with immunosuppressive
properties
Promotes EOC dissemination
via induction of P-cadherin
Loss of NKX3.1 causes PINlike lesions in mice
Co-operates with loss of PTEN
to induce prostate cancer
progression
Loss of HOXA5 promotes cell
cycle deregulation and
metastasis by inducing loss of
p53 and promoting expression
of Twist
Loss of HOXA5 induces
genomic instability by downregulating expression of human
MutL homolog 1 (hMLH1)
Loss of CDX2 promotes
genomic instability by inducing
DNA repair via nonhomologous end joining (NHEJ)
pathway
Loss of CDX2 deregulates cell
cycle progression by downregulating expression of cyclin
dependent kinase inhibitors
p27Kip1 and p21/waf1/cip1

References

122-128

131-135

136-139

114, 116-118

108, 140, 141

142-144

4. Role of the homeobox gene DLX4 in tumors
DLX4, a member of the DLX family of homeobox genes, is also reported as BP1, DLX7
and DLX8

91, 145

. DLX4 is generally expressed in endometrium, placenta, trophoblast and

normal bone marrow cells but not in other normal adult tissues

146-148

. Increasing evidence

indicates that DLX4 is expressed in hematological malignancies and also solid tumors such as
EOC, breast, prostate, and lung cancers (Table 4). Previous studies in our laboratory have
demonstrated that high expression of DLX4 in tumors confers resistance to anti-proliferative
signals mediated by TGF-β, promotes genomic instability and chemoresistance in various
tumors 149, 150. DLX4 has been reported to promote invasiveness of breast cancer by inducing
expression of TWIST and inhibiting expression of E-cadherin

151, 152

. Other studies from our

laboratory have found that DLX4 is absent from normal ovary and ovarian cystadenomas 129.
On the other hand, expression of DLX4 in EOC strongly correlates with advanced disease
stage, high tumor grade and reduced overall survival of patients

129

. The ability of DLX4 to

promote EOC growth has been attributed in part to its stimulation of tumor angiogenesis 129.
However, the mechanisms by which DLX4 promotes EOC metastasis are poorly understood.
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Table 4: Examples of aberrant expression and functional significance of DLX4 in
tumors

Type of cancer

Breast

Ovarian

Prostate

Pattern of DLX4
expression in
cancers

Overexpressed in
80% of breast
cancers

Overexpressed in
~50% of EOC and
correlates with
advanced disease
stage and high tumor
grade

Functional significance of
deregulation of DLX4 in cancers







Represses BRCA1 expression
Upregulates Twist and promotes
tumor metastasis
Promotes tumor cell survival by
inducing Bcl-2 and inhibiting
apoptosis
Promotes tumor angiogenesis
by inducing expression of
VEGF and bFGF

References

130, 151-157

129

158

Overexpressed in
70% of prostatic
adenocarcinomas

Expressed in normal
Choriocarcinoma placenta and human
choriocarcinoma cell
lines



Promotes tumor cell survival

159, 160

Overexpressed in
bone marrow of 63%
of acute myeloid
leukemia (AML)
cases



Increases clonogenicity of
leukemic cells
Induces expression of c-myc

148, 161, 162

Leukemias
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C. HYPOTHESIS AND SPECIFIC AIMS
The high morbidity and mortality caused by EOC stems from its propensity to
disseminate throughout the peritoneal cavity and the inability to detect the disease at an early,
organ-confined stage. Cancer-associated ascites is enriched in growth factors and
inflammatory cytokines that promote inflammatory signaling and peritoneal metastasis.
However, the mechanisms by which EOC cells activate chronic inflammatory signaling and
by which inflammatory cytokines promote metastasis are poorly understood. The overall goal
of my study is to identify the molecular mechanisms that promote rapid metastasis of EOC.
Expression of the homeobox gene DLX4 in EOC has been found to be strongly
associated with advanced disease stage and poor survival of patients. However, the
significance of DLX4 in promoting metastasis of EOC is not known. My broad hypothesis is
that DLX4 promotes peritoneal dissemination of EOC. Specifically, I hypothesize that DLX4
promotes peritoneal dissemination of EOC by controlling inflammatory signaling.
The specific aims of my study are:
1) To determine whether DLX4 promotes peritoneal dissemination of EOC
2) To identify the mechanisms by which DLX4 controls tumor-peritoneum interactions
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CHAPTER 2: MATERIALS AND METHODS
1. Antibodies
Sources of antibodies (Abs) were as follows: DLX4 Ab (for flow cytometry, Abcam,
Cambridge, MA), DLX4 Ab (for chromatin immunoprecipitation, Abnova, Taipei, Taiwan),
CD44 Ab (for flow cytometry, BD Biosciences, San Jose, CA), CD44 Ab (for neutralization,
Abcam), phosphorylated NF-κB p65 (Ser 536) Ab (for flow cytometry, Cell Signaling
Technology, Danvers, MA). Secondary Abs were purchased from Pierce Biotechnology,
Rockford, IL and BD Biosciences.
2. Plasmids
A human DLX4 cDNA plasmid was provided by Dr. Patricia Berg (George Washington
University) 162. Flag-tagged DLX4 was subcloned into pIRES-EGFP2 vector (Clontech, Palo
Alto, CA)

149

. Flag-tagged DLX4 was also subcloned into the retroviral vector, pRetroQ

(Clontech). pGFP-VRS plasmids containing non-targeting shRNA and DLX4 shRNAs were
purchased from OriGene Technologies (Rockville, MD). IL1B cDNA was purchased from
Origene Technologies. pGipZ lentiviral vectors containing IL1B shRNA and non-targeting
shRNA were purchased from shRNA and the ORFeome Core Facility (University of Texas
MD Anderson Cancer Center, Houston, TX). The NF-κB-luciferase reporter construct
containing tandem repeats of NF-κB transcriptional response element (TRE) was purchased
from SABiosciences (Frederick, MD). pBabe-GFP-IκBα dominant negative (IκBα-DN)
construct was provided by Dr. William Hahn (Broad Institute of Harvard and MIT,
Cambridge, MA; Addgene plasmid 15264) 163.
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3. Cell culture
3.1. EOC cell lines
The EOC cell line A2780 was provided by Dr. Gordon Mills (University of Texas MD
Anderson Cancer Center). The EOC cell line 2008 was provided by Dr. Zahid Siddik
(University of Texas MD Anderson Cancer Center). Both cell lines were cultured in RPMI
1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 2mM glutamine and
penicillin-streptomycin.
3.2. Primary human mesothelial cells
Cultures of primary normal human mesothelial cells were provided by Dr. Ernst Lengyel
(University of Chicago). Mesothelial cells were obtained from normal omental tissues of
women undergoing surgery for benign conditions

164

. Cultures were maintained in RPMI

1640 medium supplemented with 20% FBS, 2mM glutamine, 100 U/ml penicillin and 100
μg/ml streptomycin.
4. Transfection and generation of stable lines
For generating A2780 stable lines, the retroviral constructs containing empty vector and
Flag-tagged DLX4 were used to transfect Ampho293 cells using Lipofectamine 2000 (Life
Technologies, Carlsbad, CA). Viral supernatants were harvested after 48 hours and used to
infect A2780 cells. Stable lines were selected with puromycin (0.5μg/ml). Lipofectamine
2000 was used for transient transfections of A2780 and 2008 cells.
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5. In vitro cell attachment assays
In vitro cell attachment assays were performed as described in Ko et al

30

. Mesothelial

cells (30,000 per well) were seeded in 96-well plates to obtain confluent monolayers. At one
day thereafter, green fluorescent protein (GFP)-expressing EOC cells (15,000 per well) were
seeded onto mesothelial cells and the plates were incubated at 37ºC for one hour. For
blocking experiments, EOC cells were pre-incubated with the CD44 blocking Ab or control
IgG at a concentration of 10μg/ml for one hour and then seeded onto mesothelial cells.
Unattached EOC cells were removed by gently washing the wells 3 times with culture media.
Attached EOC cells were viewed by immunofluorescence microscopy and cells were counted
in five random 200X microscopic fields per well in three independent experiments.
In other experiments, plates were coated with collagen I, fibronectin or laminin (SigmaAldrich, St. Louis, MO) at a concentration of 0.5μg/well and the plates were incubated at 4ºC
overnight. Plates were then washed 2 times with phosphate-buffered saline (PBS) and GFPexpressing EOC cells were seeded onto coated plates and the plates were incubated at 37ºC
for one hour. Attached cells were evaluated as described above.
6. Flow cytometry
Abs were diluted in PBS containing 1% bovine serum albumin (BSA). For cell surface
staining of CD44, tumor cells were incubated with CD44 Ab (1:10) for 30 minutes at 4°C,
washed and incubated with peridinin-chlorophyll-protein complex (PerCP)-conjugated antimouse IgG. For intracellular staining of DLX4 and phosphorylated p65, tumor cells were
fixed in 1% paraformaldehyde (20 minutes at 4°C) and permeabilized in 0.1% saponin (15
minutes at room temperature). Following washing, cells were incubated with Abs to DLX4
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(1:20) and phosphorylated NF-κB p65 (1:500) for 30 minutes at 4°C, washed and incubated
with PerCP- or phycoerythrin (PE)- conjugated secondary Abs. Staining was detected by
flow cytometry (FACS Calibur, BD Biosciences).
7. ELISA
ELISA kit for IL-1β was purchased from R&D Systems (Minneapolis, MN). Cells were
lysed using M-PER buffer (Pierce Biotechnology) and cell lysates were prepared as per the
manufacturer’s instructions. Intracellular IL-1β levels were assayed in the cell lysates as per
the manufacturer’s instructions and normalized to the total cellular protein content in three
independent experiments.
8. Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells using PureLink RNA mini kit (Invitrogen, Carlsbad,
CA) as per the manufacturer’s instructions. 1 μg of RNA was used to synthesize cDNA using
qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) as per the manufacturer’s
instructions. Transcript levels were analyzed on CFX96 Touch Real-Time PCR Detection
System (Bio-Rad, Hercules, CA) using primers listed in Table 5 and iTaq Universal SYBR®
Green Supermix (Bio-Rad) as per the manufacturer’s instructions. Target gene transcript
levels were normalized to levels of ribosomal protein RPL32. mRNA levels were assayed in
triplicate in two independent experiments.
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Table 5: Primers for qRT-PCR

Gene

Sequence

Forward

5’- GGCTTTCAATAGCACCTTGC - 3’

Reverse

5’- ACACCCCTGTGTTGTTTGCT - 3’

Forward

5’- CAGGTGCTGAACATCACGGACA - 3’

Reverse

5’- CTTCAGGGACAAGACCACTGTG - 3’

Forward

5’- GGATTCTCCAGAAGGTGGTTTCG - 3’

Reverse

5’- TGCCACCAAGTTTCCCATCTCC - 3’

Forward

5’- CCACAGACCTTCCAGGAGAATG - 3’

Reverse

5’- GTGCAGTTCAGTGATCGTACAGG - 3’

Forward

5’- ACAAAGCACATGCTGCCCAGTG - 3’

Reverse

5’- TTCCACGATGGCTTTGCGGTTC - 3’

CD44

CDH3

ITGB1

IL1B

RPL32
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9. Chromatin Immunoprecipitation (IP)
Chromatin IP assays were performed using EZ-ChIP Chromatin Immunoprecipitation
Kit (Upstate Biotechnology, Temecula, CA). Cells were crosslinked by adding formaldehyde
to a final concentration of 1% for 10 minutes at room temperature. Glycine was then added at
room temperature for 5 minutes to quench formaldehyde. Cells were then washed twice with
1X PBS and harvested. Cell pellets were lysed with Sodium Dodecyl Sulfate (SDS) lysis
buffer (Upstate Biotechnology) and then sonicated to generate fragments of DNA of ~2001000 base pairs in length. Sheared chromatin was first pre-cleared by incubating with protein
G agarose beads for 1 hour. Pre-cleared chromatin was then incubated with Abs to DLX4 or
normal IgG overnight at 4°C. Protein G agarose beads were then added and incubated for 1
hour at 4°C. The agarose-antibody/chromatin complex was washed as per the manufacturer’s
instructions followed by elution of protein/DNA complexes, reverse crosslinking of
protein/DNA complexes at 65°C overnight and purification of DNA using spin columns.
Purified DNA was used to amplify fragments of the IL1B promoter by PCR. PCR products
were analyzed on a 3% agarose gel. The primers used for PCR amplification are listed in
Table 6.
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Table 6: Primers for chromatin IP assays

Gene

IL1

GAPDH
(Glyceraldehyde 3phosphate
dehydrogenase)

Sequence

Forward

5’- GGTAGAGACCCACACCCTCA - 3’

Reverse

5’- CATGGAAGGGCAAGGAGTAG - 3’

Forward

5’- TACTAGCGGTTTTACGGGCG - 3’

Reverse

5’- TCGAACAGGAGGAGCAGAGAGCGA - 3’
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10. Luciferase reporter assays
Cells were plated at a density of 1-2 x 105 cells per well in 12-well plates and cotransfected with expression plasmids (500ng/well) and NF-κB Luc or Negative Luc reporter
plasmids (100ng/well) using Lipofectamine 2000 reagent. At 24 hours after transfection,
luciferase activities were assayed using the Dual-reporter assay kit (Promega, Madison, WI).
Efficiencies of transfections were normalized using Renilla luciferase readings. Relative
luciferase activities were assayed in three independent experiments.
11. Statistical analysis
Statistical significance for differences in the number of peritoneal implants in mice was
assessed by Mann-Whitney U-Test. Statistical significance for in vitro assays was calculated
by Student’s t-test. All statistical analyses were performed using STATISTICA10 software
(StatSoft, Inc.). P values < 0.05 were considered significant.
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CHAPTER 3: ROLE OF DLX4 IN PERITONEAL DISSEMINATION OF EOC
A. RATIONALE
More than 60% of EOC patients are diagnosed with advanced stage disease that has
spread throughout the peritoneal cavity 8. EOC cells typically spread by shedding into the
circulating fluid that transports the cells throughout the peritoneal cavity. EOC cells then
implant on to the mesothelial linings of the peritoneal and abdominal organs including the
mesentery, diaphragm, omentum and cavity wall (Figures 3, 4). However, the mechanisms
that enable implantation of EOC cells on to peritoneal surfaces are poorly understood.
Previous studies from our laboratory have found that the homeobox gene DLX4 is highly
expressed in advanced stage EOC 129. High expression of DLX4 correlated with disease stage
and poor survival of patients

129

. However, the mechanisms by which DLX4 promotes

peritoneal metastasis of EOC are not known. In this chapter, the goal of my studies is to
determine whether DLX4 promotes peritoneal dissemination of EOC.
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B. RESULTS
1. DLX4 promotes implantation of EOC cells onto peritoneal surfaces in i.p. mouse
xenograft models
In advanced stage disease, exfoliated EOC cells are transported by the circulating
peritoneal fluid (Figure 4). Thereafter, these circulating EOC cells implant onto the
mesothelial cells that line the peritoneal cavity. Nests of tumor cells are frequently observed
on the mesentery, diaphragm and omentum of patients (Figure 3). Our laboratory has
previously generated xenografts by i.p. inoculation of female nude mice with cells of GFPexpressing A2780 EOC lines that stably express or lack DLX4

129

. To initiate this study, I

analyzed tissues of mice inoculated with vector-control A2780 cells and with DLX4expressing A2780 cells (+DLX4) to determine the degree of implantation of EOC cells to
sites within the peritoneal cavity. Significantly higher numbers of implants were observed on
the mesentery and diaphragm of mice inoculated with +DLX4 A2780 cells as compared to
mice inoculated with equal numbers of vector-control A2780 cells (P < 0.01) (Figure 9). This
observation raised the possibility that DLX4 promotes attachment of EOC cells to the
mesothelial linings of the peritoneal and abdominal organs.
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Figure 9. DLX4 increases the number of peritoneal tumor implants in i.p. mouse
xenograft models
Female nude mice (n=5 per group) were inoculated i.p. with 3x106 cells of vector-control and
+DLX4 A2780 cell lines and sacrificed 4 weeks thereafter. Numbers of implants were
counted on hematoxylin-eosin (HE) stained xenograft tissue sections from A) diaphragm and
B) mesentery of mice. Bar, 2mm.
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2. DLX4 promotes in vitro attachment of EOC cells to mesothelial cells
For this study, two EOC cell lines were used as models. For determining the effect of
overexpressing DLX4, I used retrovirally transduced stable A2780 cell lines that express
either empty vector or DLX4. For determining the effect of inhibiting DLX4, I used 2008, an
EOC cell line that endogenously expresses DLX4 at a high level 129. Knockdown of DLX4 in
2008 cells was carried out by using two shRNA plasmids that targeted two different sites
within DLX4 (shDLX4-A and shDLX4-B). Overexpression of DLX4 in A2780 cell lines and
knockdown of DLX4 in 2008 cell lines was assayed and quantified by qPCR analysis (not
included) and flow cytometric analysis of intracellular staining of DLX4 (Figure 10).
Attachment of EOC cells within the peritoneal cavity is mediated via two primary
mechanisms: attachment of EOC cells to the mesothelial cells lining the peritoneal cavity and
attachment to the sub-mesothelial ECM

23-26

. To determine whether DLX4 promotes

attachment of EOC cells to peritoneal mesothelial cells, in vitro cell attachment assays were
performed (Figure 11) by seeding equal numbers of GFP-expressing vector-control A2780
cells and +DLX4 A2780 cells on to confluent monolayers of primary normal human
mesothelial cells. Significantly higher number of +DLX4 A2780 cells were attached to the
mesothelial cells as compared to the vector-control A2780 cells (P < 0.01) (Figure 12A).
Conversely, 2008 cells in which DLX4 was knocked down (shDLX4-A and shDLX4-B)
showed significantly reduced attachment to mesothelial cells as compared to control 2008
cells (empty vector and non-targeting) (P < 0.01) (Figures 12B, 12C). These findings
indicate that DLX4 promotes attachment of EOC cells to mesothelial cells.
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To determine whether DLX4 promotes attachment of EOC cells to components of the
sub-mesothelial ECM, in vitro cell attachment assays were performed by seeding equal
numbers of GFP-expressing A2780 cells (empty vector and +DLX4) onto plates coated with
ECM components, i.e. collagen I, fibronectin and laminin. No significant difference was
observed between the numbers of vector-control and +DLX4 A2780 cells that attached to the
components of the ECM (Figure 13). Similarly, no significant difference was observed in the
numbers of DLX4-knockdown 2008 cells and control 2008 cells that attached to the ECM
components (Figure 13). Together, these observations indicate that DLX4 promotes
attachment of EOC cells to peritoneal mesothelial cells but not to the components of the
ECM.
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Figure 10. Overexpression of DLX4 in A2780 cells and knockdown of DLX4 in 2008
cells
Flow cytometric analysis of intracellular staining of DLX4 in (A) A2780 cell lines that
express empty vector and DLX4 and in (B) 2008 cells that express empty vector, nontargeting shRNA and shRNAs that target two different sites within DLX4 (shDLX4-A and
shDLX4-B). Mean fluorescence intensities (MFI) of staining are indicated.
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Figure 11. In vitro cell attachment assays
Equivalent numbers of GFP-expressing EOC cells (shown in green) were seeded onto
confluent monolayers of primary normal human mesothelial cells (shown in yellow) in 96well plates or on wells coated with collagen I, fibronectin or laminin. Cell attachment was
assayed at one hour after seeding. Attached cells were viewed by immunofluorescence
microscopy and counted in five random 200X microscopic fields per well. Each assay was
performed in triplicate.
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Figure 12. DLX4 promotes in vitro attachment of EOC cells to peritoneal mesothelial
cells
Equivalent numbers of GFP-expressing EOC cells were seeded onto confluent monolayers of
peritoneal mesothelial cells. After one hour, numbers of attached cells were counted in 5
random 200X microscopic fields per well. Numbers of (A) Attached vector-control and
+DLX4 A2780 cells and (B) Control and DLX4-knockdown 2008 cells and (C) A
representative picture of GFP-expressing 2008 cells attached to the monolayer of mesothelial
cells. Shown in (A) and (B) are mean ± sd values of three independent attachment assays.
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Figure 13. DLX4 does not mediate attachment of EOC cells to components of the ECM
Equivalent numbers of vector-control and +DLX4 A2780 cells and control and DLX4knockdown 2008 cells were seeded on wells that were (A) uncoated or coated with (B)
collagen I, (C) fibronectin and (D) laminin. Numbers of attached cells were counted after 1
hour in five random 200X microscopic fields per well. Shown are mean ± sd values of three
independent attachment assays.
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3. DLX4 induces expression of CD44 in EOC cells
Attachment of EOC cells to the mesothelium lining the peritoneal cavity is mediated by
various cell adhesion molecules such as P-cadherin, β1 integrin and CD44 24, 32, 33, 42. Because
DLX4 is a transcription factor, DLX4 might promote attachment of EOC cells to mesothelial
cells by inducing expression of these cell adhesion molecules. To investigate this possibility,
I initially performed qRT-PCR to evaluate mRNA levels of candidate genes that encode cell
adhesion molecules when DLX4 was overexpressed or knocked down. When DLX4 was
overexpressed in A2780 cells, there was more than a 10-fold induction in CD44 mRNA
levels as compared to levels in vector-control A2780 cells (P <0.001) (Figure 14A).
However, there was no induction in mRNA levels for P-cadherin (CDH3) or β1 integrin
(ITGB1) (Figures 14B, 14C). Conversely, when DLX4 was knocked down in 2008 cells,
there was a significant reduction in CD44 mRNA levels (P < 0.01) (Figure 14A). No
reduction in CDH3 or ITGB1 mRNA levels was observed after knockdown of DLX4
(Figures 14B, 14C).
To further confirm the induction of CD44 by DLX4, I analyzed cell surface levels of
CD44 protein by flow cytometry in vector-control and +DLX4 A2780 cells and in control
and DLX4-knockdown 2008 cells. This analysis showed an induction in CD44 levels when
DLX4 was overexpressed in A2780 cells (Figure 15A) and a reduction in CD44 levels when
DLX4 was knocked down in 2008 cells (Figure 15B). These findings indicate that DLX4
induces expression of CD44.
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Figure 14. DLX4 induces expression of CD44 but not P-cadherin or β1 integrin
A2780 cells that expressed empty vector or DLX4 and 2008 cells that expressed empty
vector, non-targeting shRNA or shRNAs for DLX4 (shDLX4-A and shDLX4-B) were
assayed by qRT-PCR for mRNA transcript levels of (A) CD44, (B) CDH3 (encoding Pcadherin) and (C) ITGB1 (encoding β1 integrin). All samples were analyzed in triplicates in
two independent experiments. Error bars represent standard deviation.
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Figure 15. DLX4 induces expression of CD44
Cell surface levels of CD44 were assayed by flow cytometry in (A) A2780 cells that
expressed empty vector or DLX4 and in (B) 2008 cells that expressed empty vector, nontargeting shRNA or shRNAs against DLX4 (shDLX4-A and shDLX4-B).
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4. DLX4 promotes attachment of EOC cells to peritoneal mesothelial cells via CD44
The glycoprotein CD44 is a major receptor for HA that is synthesized by peritoneal
mesothelial cells

52, 53

mesothelial cells

24, 53, 54

. Binding of CD44 to HA promotes attachment of EOC cells to
. Because my findings indicated that DLX4 promotes attachment of

EOC cells to mesothelial cells and also induces CD44, I evaluated whether DLX4 promotes
attachment of EOC cells to mesothelial cells via CD44. In vitro cell-attachment assays were
performed in which vector-control and +DLX4 A2780 cells were pre-incubated with a
neutralizing Ab against CD44 prior to seeding onto mesothelial cells (Figure 16). The Ab
was directed against an epitope close to the HA-binding domain of CD44 (Figure 16).
Treatment with this neutralizing CD44 Ab blocked the attachment of +DLX4 A2780 cells to
the peritoneal mesothelial cells, whereas treatment with control IgG had no effect (Figure
17). In contrast, treatment with CD44 Ab had no significant effect on the ability of vectorcontrol A2780 cells to attach to mesothelial cells (Figure 17). This observation was
consistent with my previous findings that vector-control A2780 cells express very low levels
of CD44 (Figures 14A, 15). Together, these findings indicate that DLX4 promotes
attachment of EOC cells to peritoneal mesothelial cells via CD44.
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Figure 16. Mechanism of CD44-mediated attachment of EOC cells to mesothelial cells
The cell adhesion molecule CD44, which is present on EOC cells, is a major receptor for HA
that is synthesized by mesothelial cells

52, 53

. Interaction of CD44 and HA facilitates

implantation of EOC cells to mesothelial cells lining the peritoneal cavity 24, 53, 54. The CD44
blocking Ab is directed against an epitope very close to the HA-binding domain of CD44 and
prevents binding of CD44 to HA 165.
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Figure 17. Neutralization of CD44 blocks the ability of DLX4-expressing EOC cells to
attach to mesothelial cells
GFP-expressing empty vector and +DLX4 A2780 cells were pre-incubated with CD44
blocking Ab or normal IgG for 1 hour and then seeded onto confluent monolayers of
mesothelial cells. Attachment of A2780 cells to the mesothelial monolayer was assayed at 1
hour after seeding. Attached cells were counted in 5 random 200X microscopic fields. Shown
are mean ± sd values of three independent attachment assays.
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C. CONCLUSION
My studies in Chapter 3 demonstrate that overexpression of DLX4 in EOC cells induces
CD44 expression and promotes attachment of EOC cells to mesothelial cells. Conversely,
knockdown of DLX4 in EOC cells down-regulates expression of CD44 and reduces
attachment of EOC cells to mesothelial cells. Furthermore, blocking CD44 in DLX4overexpressing EOC cells hinders their ability to attach to mesothelial cells. Together, these
findings indicate that DLX4 promotes attachment of EOC cells to peritoneal mesothelial cells
by inducing expression of CD44. The molecular mechanisms by which DLX4 induces
expression of CD44 in EOC cells will be discussed in Chapter 4.
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CHAPTER 4: MECHANISMS OF DLX4 IN PERITONEAL DISSEMINATION AND
INFLAMMATORY SIGNALING IN EOC
A. RATIONALE
Formation of ascites is one of the hallmarks of advanced-stage EOC

56

. Ascites of EOC

patients contains a wide variety of pro-inflammatory cytokines such as IL-8, IL-6 and IL-1β
that stimulate tumor progression63, 66, 67, 69, 72, 73. Expression of these cytokines is associated
with poor prognosis of EOC patients

64

. However, the precise mechanisms by which

inflammatory signaling in EOC contributes to peritoneal dissemination of tumors is poorly
understood.
Studies in Chapter 3 demonstrated that DLX4 promotes the attachment of EOC cells to
peritoneal mesothelial cells (Figure 12). My studies identified that this stimulatory effect of
DLX4 is mediated by its ability to induce expression of CD44 on the surface of EOC cells
(Figures 14A, 15, 17). In this chapter, the goal of my studies is to identify the mechanisms by
which DLX4 induces expression of CD44 in EOC cells.
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B. RESULTS
1. DLX4 induces expression of IL-1β
Because DLX4 primarily functions as a transcription factor, I initially hypothesized that
DLX4 might directly activate CD44 transcription. However, no potential DLX4 binding sites
were identified in the CD44 promoter region by performing analysis of transcription factor
binding sites (Genomatix). Several studies have demonstrated that the pro-inflammatory
cytokine IL-1β promotes expression of CD44 in other inflammatory diseases such as
arteriosclerosis and rheumatoid arthritis 166, 167. Other studies have identified that IL-1β levels
are elevated in EOC patients

70

. I therefore hypothesized that DLX4 induces expression of

CD44 in EOC cells by stimulating production of IL-1β.
To determine whether DLX4 induces expression of IL-1β in EOC cells, I evaluated the
expression of IL-1β when DLX4 was overexpressed or knocked down. IL1B mRNA levels
were significantly higher in +DLX4 A2780 cells as compared to the vector control A2780
cells (P < 0.001) (Figure 18A). Conversely, IL1B mRNA levels were significantly lower in
DLX4-knockdown 2008 cells as compared to control 2008 cells (P < 0.001) (Figure 18A).
Similarly, IL-1β protein levels were induced when DLX4 was overexpressed in A2780 cells
and were reduced when DLX4 was knocked down in 2008 cells (Figure 18B). These results
demonstrate that DLX4 induces expression of IL-1β in EOC cells.
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Figure 18. DLX4 induces expression of IL-1β
mRNA transcript levels of IL1B were assayed by qRT-PCR in (A) empty vector control and
+DLX4 A2780 cells and (B) control (non-targeting) and DLX4-knockdown (shDLX4-A)
2008 cells. Shown are mean ± sd values of three independent assays.
Protein levels of IL-1β were assayed by ELISA in (C) empty vector control, +DLX4 and
+DLX4 A2780 cells transfected with non-targeting shRNA and IL1B shRNA and (D) control
(non-targeting), DLX4-knockdown (shDLX4-A) and DLX4-knockdown 2008 cells that were
reconstituted with IL1B. Shown are mean ± sd values of three independent assays.
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2. IL1B is a direct transcriptional target of DLX4
DLX4 is primarily known to function as a transcription factor. I therefore hypothesized
that IL1B, the gene that encodes IL-1β, is a direct transcriptional target of DLX4 in EOC
cells. A putative DLX4 binding motif was identified in the human IL1B promoter (Figure
19A). Binding of endogenous DLX4 to the binding site detected on the IL1B promoter was
demonstrated by chromatin IP assays in 2008 cells (Figure 19B).
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Figure 19. DLX4 directly binds to IL1B promoter
(A) Representation of the IL1B promoter with a putative DLX4 binding site (TATAAAT)
located between nucleotides -353 to -359. (B) Chromatin immunoprecipitation analysis of the
interaction of endogenous DLX4 in 2008 cells with the putative binding site identified on the
IL1B promoter. Input DNA corresponds to 1% of the chromatin solution before
immunoprecipitation. Immunoprecipitation was performed with DLX4 Ab and control IgG.
Purified DNA was amplified with primers specific to IL1B promoter region and GAPDH.
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3. DLX4 induces NF-κB transcriptional activity in EOC cells
IL-1β is known to induce canonical NF-κB signaling in tumors

74

. Because my studies

demonstrated that DLX4 induces expression of IL-1β in EOC cells, I investigated whether
DLX4 promotes NF-κB transcriptional activity in EOC cells. To accomplish this, I assayed
luciferase activity of a reporter construct driven by a synthetic promoter containing tandem
repeats of NF-κB binding sites (Figure 20A) in cells in which DLX4 was overexpressed or
knocked down. Overexpression of DLX4 in A2780 cells induced a 3-fold increase in NF-κB
transcriptional activity (P < 0.001) (Figure 20B). Conversely, knockdown of DLX4 in 2008
cells reduced NF-κB transcriptional activity by 50% (P < 0.01) (Figure 20B).
When canonical NF-κB signaling is activated, NF-κB transcription factors p65, p50 and
c-Rel translocate to the nucleus, phosphorylate, form dimers and activate NF-κB target genes
(Figure 5)

77, 88

. High level of phosphorylated p65 in EOC is associated with advanced

disease stage in patients 85-87. In subsequent studies, I evaluated levels of phosphorylated p65
in EOC cells when DLX4 was overexpressed or knocked down by flow cytometric analysis
of intracellular staining. Higher levels of phosphorylated p65 were detected in +DLX4
A2780 cells as compared to the vector-control cells (Figure 21A). Conversely, lower levels
of phosphorylated p65 were detected in DLX4-knockdown 2008 cells as compared to control
2008 cells (Figure 21B). Together, these results demonstrate that DLX4 induces NF-κB
transcriptional activity and levels of phosphorylated NF-κB transcription factor p65 in EOC
cells.
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A2780

2008

Figure 20. DLX4 induces NF-κB signaling in EOC cells
(A) An illustration of the NF-κB-driven luciferase reporter construct containing tandem
repeats of NF-κB transcriptional response elements. (B) Luciferase reporter assays were
performed to assay NF-κB transcriptional activity in empty vector and +DLX4 A2780 cells
and 2008 cells transfected with empty vector, non-targeting shRNA and shRNAs against
DLX4 (shDLX4-A and shDLX4-B). Shown are relative luciferase activities in three
independent experiments. Error bars represent standard deviation.
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Figure 21. DLX4 induces levels of phosphorylated p65 in EOC cells
Intracellular levels of phosphorylated p65 were assayed in (A) empty vector and +DLX4
A2780 cells and (B) 2008 cells transfected with non-targeting shRNA and shRNA against
DLX4 (shDLX4-A) by flow cytometry.
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4. Induction of NF-κB signaling by DLX4 in EOC cells is mediated by IL-1β
Canonical NF-κB signaling activity in tumors is triggered by several cytokines including
IL-1β

74

. My studies have demonstrated that DLX4 promotes IL-1β expression and NF-κB

transcriptional activity in EOC cells (Figures 18, 19, 20, 21). To determine whether induction
of NF-κB activity in EOC cells by DLX4 occurs due to its induction of IL-1β, I inhibited
expression of IL-1β by using shRNA against IL1B in +DLX4 A2780 cells. ELISA assays
were performed to confirm that the shRNA reduced the IL-1β level in +DLX4 A2780 cells to
the basal IL-1β level seen in vector control A2780 cells (Figure 18C). To evaluate NF-κB
transcriptional activity, luciferase reporter assays were performed using the NF-κB driven
reporter construct. Inhibition of IL-1β by shRNA in +DLX4 A2780 cells reduced the level of
NF-κB transcriptional activity almost to the level detected in vector-control A2780 cells
(Figure 22A). This finding indicates that the ability of DLX4 to stimulate NF-κB
transcriptional activity is substantially mediated by its induction of IL-1β.
To confirm my findings, I investigated whether reconstitution of IL-1β can rescue the
transcriptional activity of NF-κB when DLX4 is knocked down. To accomplish this, I
transfected IL1B cDNA into DLX4-knockdown 2008 cells. ELISA assays were performed to
confirm that transfection of IL1B cDNA in DLX4-knockdown 2008 cells restored the IL-1β
level to a level comparable to that of control 2008 cells (Figure 18D). Reconstitution of IL-1β
in DLX4-knockdown 2008 cells restored NF-κB transcriptional activity to a level
comparable to that seen in control 2008 cells (Figure 22B). These results indicate that the
induction of NF-κB transcriptional activity by DLX4 in EOC cells is mediated by its
induction of IL-1β.
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Figure 22. DLX4 induces NF-κB transcriptional activity in tumors via its induction of
IL-1β
Reporter assays using the NF-κB driven luciferase construct were performed to assay NF-κB
transcriptional activity in (A) empty vector control A2780 cells, empty vector control A2780
cells transfected with IκBα-DN, +DLX4 A2780 cells and +DLX4 A2780 cells transfected
with IκBα-DN, non-targeting shRNA and shRNA against IL1B and (B) control (nontargeting) 2008 cells, DLX4-knockdown 2008 (shDLX4-A) cells and DLX4-knockdown
2008 cells after reconstitution with IL1B cDNA. Shown are relative luciferase activities in
three independent experiments. Error bars represent standard deviation.
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5. DLX4 induces CD44 in EOC cells in an IL-1β and NF-κB-dependent manner
My studies have demonstrated that DLX4 induces expression of 1) CD44 and 2) IL-1β in
EOC cells (Figures 14A, 15, 18, 19). In subsequent experiments, I evaluated whether DLX4
induces expression of CD44 in an IL-1β-dependent mechanism. To accomplish this, I
evaluated expression of CD44 by flow cytometry when IL-1β was knocked down in +DLX4
A2780 cells. Knockdown of IL-1β in +DLX4 A2780 cells reduced the CD44 level almost to
the level seen in vector control cells (Figure 24). This finding indicates that the induction of
CD44 by DLX4 is primarily mediated by its induction of IL-1β.
CD44 has been identified as a direct transcriptional target of NF-κB

168

. Because my

studies also demonstrated that DLX4 induces NF-κB transcriptional activity in EOC cells via
IL-1β, I evaluated whether DLX4 induces CD44 expression in a NF-κB-dependent manner.
To evaluate this, I inhibited NF-κB transcriptional activity in +DLX4 A2780 cells by
expressing a dominant negative IκBα construct (IκBα-DN). This construct contains serine-32
to alanine and serine-36 to alanine substitutions

163

. IκBα-DN inhibits NF-κB signaling by

retaining the NF-κB transcription factors in the cytoplasm. When the canonical signaling
pathway is triggered by external stimuli, IKK normally phosphorylates IκBα at serine-32 and
serine-36

169

. This phosphorylation results in proteasomal degradation of IκBα and the

release of NF-κB dimers which then translocate to the nucleus and transcriptionally activate
target genes (Figure 5)

169

. Mutations at serine-32 and serine-36 of IκBα prevents the

phosphorylation and degradation of IκBα, thus retaining the NF-κB transcription factors in
the cytoplasm and blocking NF-κB signaling (Figure 23) 169.

60

I initially confirmed that IκBα-DN inhibited NF-κB transcriptional activity in +DLX4
A2780 cells by performing luciferase assays with the NF-κB-driven reporter construct
(Figure 22A). In subsequent experiments, I evaluated whether DLX4 induces expression of
CD44 in a NF-κB dependent manner. To determine this, I evaluated expression of CD44 by
flow cytometry when NF-κB transcriptional activity was blocked with IκBα-DN in +DLX4
A2780 cells. Flow cytometric analysis revealed that the CD44 level in +DLX4 A2780 cells
was reduced by IκBα-DN almost to the CD44 level seen in vector control A2780 cells
(Figure 24). Together, these findings demonstrate that DLX4 promotes expression of CD44
in EOC cells via induction of IL-1β expression and NF-κB signaling.
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Figure 23. Mechanism of IκBα-DN in abrogating NF-κB signaling
The IκBα-DN construct contains substitution mutations of its two serine residues, 32 and 36.
These mutations prevent the phosphorylation and degradation of IκBα by IKK complex.
IκBα therefore retains NF-κB dimers in the cytoplasm and thereby blocks NF-κB
transcriptional activity 169.
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Figure 24. DLX4 induces expression of CD44 in EOC cells via IL-1β and NF-κB
signaling
Cell surface expression of CD44 was assayed by flow cytometry in empty vector control
A2780 cells, +DLX4 A2780 cells and +DLX4 A2780 cells transfected with non-targeting
shRNA, IL1B shRNA and IκBα-DN.
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6. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the expression of
CD44
My previous findings demonstrated that DLX4 induces CD44 expression in an IL-1β and
NF-κB-dependent manner (Figure 24). To confirm my results, I evaluated whether
reconstitution of IL-1β in DLX4-knockdown cells can rescue the expression of CD44. To
accomplish this, I transfected DLX4-knockdown (shDLX4-A) 2008 cells with IL1B cDNA
and analyzed CD44 levels by flow cytometry. Reconstitution of IL-1β in DLX4-knockdown
2008 cells restored the CD44 level to a level comparable to that seen in control 2008 cells
(Figure 25). This finding demonstrates that DLX4 induces CD44 expression via induction of
IL-1β in EOC cells.
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Figure 25. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the
expression of CD44
CD44 expression was assayed by flow cytometry in control 2008 cells (non-targeting),
DLX4-knockdown 2008 (shDLX4-A) cells, and DLX4-knockdown 2008 cells after
reconstitution of IL-1β.
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7. DLX4 promotes EOC cell attachment to mesothelial cells via induction of IL-1β and
NF-κB transcriptional activity
My studies demonstrated that DLX4 promotes the attachment of EOC cells to peritoneal
mesothelial cells via induction of the cell adhesion molecule CD44 (Figure 17). My findings
also demonstrated that DLX4 induces CD44 expression in EOC cells via induction of IL-1β
(Figures 24, 25). In subsequent experiments, I evaluated whether DLX4 mediates the
attachment of EOC cells to mesothelial cells in an IL-1β-dependent manner. To accomplish
this, I performed in vitro cell attachment assays using GFP-expressing vector-control and
+DLX4 A2780 cells and +DLX4 A2780 cells in which IL-1β was knocked-down.
Knockdown of IL-1β in +DLX4 A2780 cells significantly inhibited the ability of these cells
to attach to mesothelial cells (P < 0.01), whereas non-targeting shRNA had no effect (Figure
26).
Because my studies demonstrated that DLX4 induces expression of CD44 in EOC cells
by stimulating NF-κB transcriptional activity (Figure 24), I evaluated whether DLX4
promotes attachment of EOC cells to mesothelial cells in an NF-κB-dependent manner. To
accomplish this, I evaluated the ability of +DLX4 A2780 cells to attach to mesothelial cells
when NF-κB was inhibited by IκBα-DN. Expression of IκBα-DN in +DLX4 A2780 cells
reduced the ability of these cells to attach to mesothelial cells almost to the level seen in
empty vector control A2780 cells (Figure 26). These results demonstrate that DLX4
promotes EOC cell attachment to mesothelial cells in an IL-1β and NF-κB-dependent
manner. These findings are consistent with my previous findings that DLX4 induces
expression of CD44 in an IL-1β and NF-κB-dependent manner (Figures 24, 25).
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Figure 26. DLX4 promotes EOC cell attachment to mesothelial cells via induction of IL1β and NF-κB
The ability of EOC cells to attach to mesothelial cells was assayed by in vitro cell attachment
assays using vector control A2780 cells, +DLX4 A2780 cells and +DLX4 A2780 cells
transfected with non-targeting shRNA, IL1B shRNA and IκBα-DN. Shown are mean ± sd
values of three independent attachment assays.
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8. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the effect of DLX4
My previous findings demonstrated that DLX4 promotes attachment of EOC cells to
peritoneal mesothelial cells in an IL-1β and NF-κB dependent manner (Figure 26). To further
confirm these results, I evaluated the effect of reconstituting IL-1β in DLX4-knockdown
EOC cells on their ability to attach to mesothelial cells. Reconstitution of IL-1β in DLX4knockdown 2008 cells rescued the ability of these cells to attach to mesothelial cells to a
level that was comparable to that of control 2008 cells (Figure 27). This finding
demonstrated that DLX4 primarily promotes attachment of EOC cells to mesothelial cells via
its induction of IL-1β in EOC cells.
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Figure 27. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the effect of
DLX4
The ability of EOC cells to attach to mesothelial cells was assayed by in vitro cell attachment
assays using control (non-targeting) 2008 cells, DLX4-knockdown (shDLX4-A) 2008 cells
and DLX4-knockdown 2008 cells that were reconstituted with IL-1β. Shown are mean ± sd
values of three independent attachment assays.
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C. CONCLUSION
My studies in Chapter 4 provide important insights into the mechanisms by which DLX4
promotes expression of CD44 and the ability of EOC cells to attach to peritoneal mesothelial
cells. My studies have identified that DLX4 directly binds to and activates the gene encoding
IL-1β in EOC cells. In addition, DLX4 induces NF-κB signaling in EOC cells via its
induction of IL-1β. Furthermore, my studies demonstrate that inhibition of IL-1β and NF-κB
signaling in +DLX4 A2780 cells significantly blocked the induction of CD44 and the ability
of these cells to attach to mesothelial cells. Conversely, reconstitution of IL-1β in DLX4knockdown 2008 cells rescues the expression of CD44 and the ability of these cells to attach
to mesothelial cells. In summary, my results indicate that DLX4 induces expression of IL-1β
and NF-κB signaling in EOC cells which in turn induce expression of CD44 and the ability
of EOC cells to attach to peritoneal mesothelial cells.
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CHAPTER 5: DISCUSSION
A. DLX4 PROMOTES ATTACHMENT OF EOC CELLS TO THE MESOTHELIUM
LINING THE PERITONEAL CAVITY
The high lethality of EOC stems from rapid peritoneal involvement of the disease and
late diagnosis. A key rate-limiting step in peritoneal metastasis of EOC is the attachment of
EOC cells to the mesothelial lining of the peritoneal cavity. My studies in Chapter 3
demonstrated that high expression of DLX4 in EOC cells promotes their attachment to the
peritoneal mesothelial cells (Figure 12). On the other hand, overexpression of DLX4 did not
promote attachment of EOC cells to the sub-mesothelial ECM components such as collagen
I, fibronectin and laminin (Figure 13). My findings demonstrate that DLX4 mediates the
attachment of EOC cells by inducing expression of the cell adhesion molecule CD44
(Figures 14A, 15, 17). However, DLX4 did not induce expression of P-cadherin and β1
integrin that also mediate EOC-peritoneal interactions (Figures 14B, 14C). The inability of
DLX4 to induce expression of β1 integrin is consistent with the inability of DLX4 to mediate
EOC cell attachment to the components of the ECM. Notably, blocking CD44 did not
completely abrogate the attachment of EOC cells to mesothelial cells (Figure 17).
Interactions between EOC cells and the peritoneum are known to be mediated by multiple
cell adhesion molecules 24, 32, 33, 42. This explains the inability of the CD44 neutralizing Ab to
completely abolish the attachment of +DLX4 EOC cells to mesothelial cells (Figure 17).
These findings are consistent with other studies that have demonstrated that using a single
neutralizing Ab against CD44, β1 integrin or P-cadherin was not sufficient to completely
block EOC cell attachment to mesothelial cells

24, 33, 42, 55

. A study by Strobel and colleagues

also demonstrated that combining CD44 and β1 integrin blocking Abs resulted in an additive
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inhibitory effect on EOC cell attachment

33

. These findings indicate that multiple cell

adhesion molecules need to be targeted simultaneously to effectively block attachment of
EOC cells to mesothelial cells. The interplay between these different cell adhesion molecules
can be a focus of future studies and provide insights for development of better targeted
therapies.
B. DLX4 PROMOTES CD44 EXPRESSION AND EOC-MESOTHELIAL CELL
INTERACTIONS BY INDUCING IL-1β EXPRESSION AND ACTIVATING NF-κB
SIGNALING
IL-1β is a pleiotropic cytokine that contributes to inflammation in numerous pathological
conditions such as cancer, arteriosclerosis, type II diabetes, rheumatoid arthritis,
osteoarthritis and cardiovascular disorders

170

. Although many other

cytokines mediate

inflammatory signaling, IL-1β is known as the ‘gatekeeper of inflammation’

171

. My studies

in Chapter 4 demonstrated that high expression of DLX4 in EOC cells induces expression of
IL-1β by direct transcriptional activation (Figures 18, 19). Inhibition of IL-1β in +DLX4
EOC cells resulted in a down-regulation of CD44 expression and reduced the ability of EOC
cells to attach to mesothelial cells (Figures 24, 26). Conversely, reconstitution of IL-1β in
DLX4-knockdown EOC cells restored CD44 levels and the ability of EOC cells to attach to
mesothelial cells (Figures 25, 27). The ability of DLX4 to promote CD44 expression and
attachment of EOC cells to mesothelial cells therefore, primarily occurs via its induction of
IL-1β in EOC cells. A study by Foster and colleagues has demonstrated that induction of
CD44 by IL-1β in vascular smooth muscle cells contributes to pathogenesis of
arteriosclerosis 167. Another study by Campo and colleagues has demonstrated that IL-1β and
HA induce CD44 expression and inflammatory signaling in rheumatoid arthritis
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166

. My

study is the first to demonstrate the significance of IL-1β in inducing CD44 expression in
controlling cell-cell interactions that mediate metastasis of EOC.
IL-1β induces the NF-κB signaling pathway in a wide variety of physiological and
pathological conditions

77

. My findings in Chapter 4 demonstrated that high expression of

DLX4 stimulates NF-κB signaling in EOC cells via its induction of IL-1β (Figures 20, 21,
22). Moreover, inhibition of NF-κB signaling in +DLX4 EOC cells down-regulated CD44
levels and decreased the ability of EOC cells to attach to mesothelial cells (Figures 24, 26).
These results indicate that DLX4 induces expression of CD44 and the attachment of EOC
cells to peritoneal mesothelial cells by activating NF-κB signaling in EOC cells. My
functional studies therefore support findings of clinical studies that identified a strong
correlation between activated NF-B signaling in EOC and advanced disease stage 84-87.
Substantial evidence indicates that NF-κB activates expression of a wide variety of target
genes that promote tumor cell survival, tumor angiogenesis and metastasis

74

. For example,

NF-κB promotes tumor angiogenesis by induction of pro-angiogenic growth factors such as
VEGF, IL-6 and IL-8 in multiple types of tumors including EOC

69, 172-174

. NF-κB can also

promote epithelial-mesenchymal transition (EMT) by transcriptional upregulation of Twist 1
175

. However, NF-κB is also known to have pro-apoptotic functions in certain cell types and

conditions. For example, a study by Ryan and colleagues demonstrated that p53 can induce
tumor cell death via activation of MEK1 and NF-κB signaling

176

. Another study by Rocha

and colleagues demonstrated that p53 downregulates cyclin D1 expression by inhibiting Bcl3, a member of the IκB family of proteins and a transcriptional co-activator for NF-κB
transcription factor p52

177

. These authors found that p53 induces formation of p52/histone

deacetylase1 (HDAC1) repressor complexes, which replaces Bcl-3/p52 activator complexes
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and thereby represses transcription of the gene encoding cyclin D1 177. A study by Yang and
colleagues demonstrated that NF-κB signaling can have dual functions in EOC

178

. On one

hand, NF-κB has a tumor-suppressive functions by sensitizing EOC cells to apoptosis
induced by paclitaxel and carboplatin. On the other hand, NF-κB has tumor-promoting
functions in aggressive forms of EOC and contributes to chemoresistance 178. Because DLX4
is expressed in advanced-stage and aggressive forms of EOC

129

, my findings that induction

of NF-κB signaling in DLX4-expressing EOC cells contributes to EOC progression are
consistent with other studies that have identified a tumor-promoting role of NF-κB in
advanced stage tumors.
C. MULTIPLE ROLES OF DLX4 IN TUMOR PATHOGENESIS
My studies demonstrated that DLX4 induces expression of CD44 in EOC cells and
promotes their attachment to mesothelial cells by inducing expression of IL-1β and NF-κB
signaling (Figure 24, 26). However, by inducing IL-1β and NF-κB signaling, DLX4 could
also stimulate a variety of other processes that promote progression of EOC. IL-1β has been
reported to confer chemoresistance in pancreatic carcinoma cell lines

179

. IL-1β also

promotes tumor vascularization in lung cancers via induction of VEGF 180. IL-1β and TNF-α
have been implicated in the induction of hypoxia inducible factor-1 (HIF-1) expression in
hepatoma cells, which in turn induces VEGF and tumor angiogenesis

181

. IL-1β, TNF-α and

interferon-γ (IFN-γ) also stimulate expression of inducible nitric oxide synthase (iNOS) in
various tumors 182. Nitric oxide, the product of iNOS, plays an important role in promotion of
tumor angiogenesis by regulating HIF-1 and VEGF expression in tumors 182. Previous studies
from our laboratory have demonstrated that DLX4 promotes EOC growth and angiogenesis
by inducing expression of pro-tumorigenic factors such as VEGF and fibroblast growth
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factor-2 (FGF-2)

129

. Since expression of VEGF is activated by IL-1β and NF-κB signaling,

my findings could explain the mechanism by which DLX4 induces VEGF expression and
angiogenesis in EOC.
In addition to EOC, DLX4 is overexpressed in other types of solid tumors including
breast and prostate cancers and in leukemias

153, 155, 156, 158, 162

. The mechanisms by which

DLX4 promotes progression of other types of tumors are not well understood. DLX4 is
highly expressed in inflammatory breast cancers (IBCs), an aggressive subtype of breast
cancer

156

. My findings that DLX4 stimulates NF-κB signaling raise the possibility that

DLX4 might also promote the aggressive behavior of IBCs. Some specific sets of homeobox
genes have been found to act similarly in different types of tumors. One such example is
HOXB7 which is overexpressed in EOC, melanoma and breast cancers

122, 125, 126

. Several

studies have demonstrated that HOXB7 promotes tumor growth and angiogenesis via
upregulation of FGF-2 in these different types of tumors 122, 125-127. On the other hand, other
sets of homeobox genes act differently in different types of tumors. One example is HOXA9.
HOXA9 has been demonstrated to have tumor promoting properties in EOC and
glioblastomas

136-139

. Expression of HOXA9 in EOC cells induces stromal cells to produce

growth factors that support tumor growth

137

. HOXA9 also promotes peritoneal

dissemination of EOC by inducing the cell adhesion molecule P-cadherin

139

. In contrast,

HOXA9 has tumor-suppressive functions in breast cancers 183. HOXA9 has been reported to
prevent progression of breast cancers by maintaining BRCA1 expression

183

. My study has

shown that high expression of DLX4 promotes inflammatory signaling and peritoneal
dissemination of EOC via induction of IL-1β and NF-κB signaling. However, it remains to
be determined whether DLX4 promotes progression of other types of tumors by stimulating
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NF-κB signaling. Further investigation of the role of DLX4 in controlling NF-κB signaling in
tumors will provide insights into the therapeutic targeting of the NF-κB signaling pathway.
D. THERAPEUTIC IMPLICATIONS
Because DLX4 is a transcription factor that shares functional domains in common with
other family members, it may be difficult to specifically target DLX4 for therapeutic
purposes. On the other hand, inhibiting the downstream effectors of DLX4, i.e. IL-1β and the
NF-κB signaling pathway may be a promising strategy. Several IL-1 therapeutics such as IL1 receptor antagonists, anti-IL-1 monoclonal Abs, soluble IL-1 receptor II (IL-1RII), IL-1β
converting-enzyme (ICE) inhibitors and IL-1 ligand traps are being currently used in the
treatment of rheumatoid arthritis 184. Such novel treatments could be applied for the treatment
of cancer. In addition, agents that target the NF-κB signaling pathway could be an effective
therapeutic strategy

185

. For example, Bortezomib is a proteasome inhibitor that blocks NF-

κB signaling and is already in use for treatment of multiple myeloma and mantle cell
lymphoma

186

. Moreover, inhibition of CD44-HA interaction and EOC cell adhesion using

CD44 monoclonal Abs or small molecule inhibitors could be another possible strategy for
treatment of advanced-stage EOC

187, 188

. Further studies examining the effect of these

inhibitors in EOC will provide insights into strategies for effective treatment for advanced
stages of this disease.
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E. CONCLUSION
The high mortality of EOC primarily stems from the rapid peritoneal dissemination of
the disease and the inability to detect the disease at an early stage. The mechanisms that
control tumor-peritoneum interactions are not well understood. My study supports a model in
which DLX4 promotes CD44-mediated peritoneal attachment of EOC via induction of the
pro-inflammatory cytokine IL-1β and activation of NF-κB signaling (Figure 28). Further
study of the regulation and function of the NF-κB signaling pathway and its activating
ligands and downstream effectors could yield important insights into possible therapeutic
targets and new treatment strategies for patients with advanced-stage and chemoresistant
EOC.
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Figure 28. Model of the mechanism by which DLX4 promotes intraperitoneal
dissemination of EOC
DLX4 promotes CD44-mediated attachment of EOC cells to the peritoneal mesothelial cells
by inducing expression of IL-1β and activating NF-κB signaling
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